Abstract
Successful treatment of steroid-refractory aGVHD (SR-GVHD) following allogeneic hematopoietic cell transplantation remains a significant challenge. Because of their immunomodulatory properties and safety profile, adult mesenchymal stem cells (MSCs) have been proposed as a treatment for SR-GVHD. Intravenous allogeneic MSC therapy (Prochymal®) for SR-GVHD was independently evaluated in the pediatric subset of a double-blind, placebo-controlled study (Protocol 280).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
